ReviewCancer metastasis reviews2014
Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.
Review in Cancer metastasis reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- CHFR drives gastric cancer stemness and hepatic metastasis by suppressing ITCH-mediated ubiquitination and degradation of OCT4.Biology direct · 2026Article
- The Methylation Level of Circulating Tumor DNA Predicts Prognosis for Stage I-III Colorectal Cancer.Journal of gastrointestinal cancer · 2026Article
- CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.NPJ breast cancer · 2025Article
- The Possibility of DNA Methylation for Precision Medicine in Colorectal Cancer.Juntendo medical journal · 2025Review
- Methylation of CpG Sites as Biomarkers Predictive of Drug-Specific Patient Survival in Cancer.Cancer informatics · 2022Article
- CHFR and Paclitaxel Sensitivity of Ovarian Cancer.Cancers · 2021Article
- miRNA dysregulation is an emerging modulator of genomic instability.Seminars in cancer biology · 2021Review
- CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1.Cell death & disease · 2021Article
- Childhood DNA methylation as a marker of early life rapid weight gain and subsequent overweight.Clinical epigenetics · 2021Article
- Identification of a Novel Epigenetic Signature CHFR as a Potential Prognostic Gene Involved in Metastatic Clear Cell Renal Cell Carcinoma.Frontiers in genetics · 2021Article
- CHFR promotes the migration of human gastric cancer cells by inducing epithelial-to-mesenchymal transition in a HDAC1-dependent manner.OncoTargets and therapy · 2019Article
- Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.Neoplasia (New York, N.Y.) · 2019Article
- CHFR Promoter Hypermethylation Is Associated with Gastric Cancer and Plays a Protective Role in Gastric Cancer Process.Journal of Cancer · 2019Review
- Epigenetic heterogeneity in cancer.Biomarker research · 2019Review
- Review
- Clinicopathological significance ofOncotarget · 2018Article
- Clinicopathological significance ofOncotarget · 2017Article
- The diagnostic and prognostic value ofOncotarget · 2017Article
- Pattern recognition for predictive, preventive, and personalized medicine in cancer.The EPMA journal · 2017Review
- Toward Precision Healthcare: Context and Mathematical Challenges.Frontiers in physiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 3 countries.
Funding
Abstract
Novel insights in the biology of cancer have switched the paradigm of a "one-size-fits-all" cancer treatment to an individualized biology-driven treatment approach. In recent years, a diversity of biomarkers and targeted therapies has been discovered. Although these examples accentuate the promise of personalized cancer treatment, for most cancers and cancer subgroups no biomarkers and effective targeted therapy are available. The great majority of patients still receive unselected standard therapies with no use of their individual molecular characteristics. Better knowledge about the underlying tumor biology will lead the way toward personalized cancer treatment. In this review, we summarize the evidence for a promising cancer biomarker: checkpoint with forkhead and ring finger domains (CHFR). CHFR is a mitotic checkpoint and tumor suppressor gene, which is inactivated in a diverse group of solid malignancies, mostly by promoter CpG island methylation. CHFR inactivation has shown to be an indicator of poor prognosis and sensitivity to taxane-based chemotherapy. Here we summarize the current knowledge of altered CHFR expression in cancer, the impact on tumor biology and implications for personalized cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.